AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Comet Resources Ltd

0.200

0.000

Volume:- -

Turnover:- -

Market Cap:13.83M

PE:-6.78

High:0.200

Open:0.200

Low:0.200

Close:0.200

52wk High:0.200

52wk Low:0.200

Shares:69.16M

Float Shares:26.19M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.030

EPS(LYR):-0.030

ROE:-53.62%

ROA:-16.18%

PB:4.73

PE(LYR):-6.78

Loading ...

Overview Company News Filings

GUIDANCE: (CRL) Charles River Laboratories Expects 2026 Adjusted EPS Including Impact of Planned Divestitures Range $10.80 - $11.30

MT Newswires Live

GUIDANCE: (CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $10.70 - $11.20, vs. FactSet Est of $11

MT Newswires Live

A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Momentum

Simply Wall St.

Why Charles River (CRL) Is Up 9.1% After Naming Long‑Time Insider Birgit Girshick CEO

Simply Wall St.

Did Lower Guidance and Weak Earnings Just Shift Charles River Laboratories' (CRL) Investment Narrative?

Simply Wall St.

A Fresh Look at Charles River Laboratories (CRL) Valuation Following Recent Share Price Momentum

Simply Wall St.

Charles River Laboratories Collaborates With X-Chem to Boost Hit Identification Capabilities

MT Newswires Live

S&P 500 Posts Weekly Gain to Record Close, Led by Health Care Amid Pfizer Deal

MT Newswires Live

Charles River Labs Shares Rise After Barclays Upgrade

MT Newswires Live

Charles River Laboratories (CRL): Valuation Perspectives After CFO Transition, Guidance Reaffirmation, and New Oncology Partnerships

Simply Wall St.

Charles River Laboratories Says CFO to Step Down

MT Newswires Live

Insulet Appoints Flavia Pease Finance Chief

MT Newswires Live

Charles River Laboratories International (CRL) Expands Oncology Partnerships With PICI and CHLA

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CRL.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CRL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CRL.AU\",,,,,undefined,":{"symbol":"CRL.AU","market":"AU","secType":"STK","nameCN":"Comet Resources Ltd","latestPrice":0.2,"timestamp":1771995600000,"preClose":0.2,"halted":9,"volume":0,"delay":0,"changeRate":0,"nameEN":"Comet Resources Ltd","floatShares":26192756,"shares":69159244,"eps":-0.029502,"marketStatus":"Not Yet Opened","change":0,"latestTime":"02-25 16:00:00 AEDT","open":0.2,"high":0.2,"low":0.2,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.029502,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1772060400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.2,"openAndCloseTimeList":[[1771974000000,1771995600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CRL.AU\",,,,,undefined,":{"symbol":"CRL.AU","floatShares":26192756,"roa":"-16.18%","roe":"-53.62%","lyrEps":-0.029502,"shares":69159244,"dividePrice":0,"high":0.2,"amplitude":0,"preClose":0.2,"low":0.2,"week52Low":0.2,"pbRate":"4.73","week52High":0.2,"institutionHeld":0,"latestPrice":0.2,"eps":-0.029502,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.029502,"open":0.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRL.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-01-31","symbol":"CRL.AU","reason":null,"defaultRemindTime":1706655600000,"announcedDate":"2024-01-30","type":"delisting","dateTimestamp":1706619600000},{"market":"AU","date":"2022-11-14","symbol":"CRL.AU","defaultRemindTime":1668380400000,"type":"split","dateTimestamp":1668344400000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"AU","date":"2022-07-20","symbol":"CRL.AU","defaultRemindTime":1658275200000,"type":"split","dateTimestamp":1658239200000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRL.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRL.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614990081","title":"GUIDANCE: (CRL) Charles River Laboratories Expects 2026 Adjusted EPS Including Impact of Planned Divestitures Range $10.80 - $11.30","url":"https://stock-news.laohu8.com/highlight/detail?id=2614990081","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614990081?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:13","pubTimestamp":1772021623,"startTime":"0","endTime":"0","summary":"GUIDANCE: (CRL) Charles River Laboratories Expects 2026 Adjusted EPS Including Impact of Planned Divestitures Range $10.80 - $11.30","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRL.AU","CRL"],"gpt_icon":0},{"id":"2612484704","title":"GUIDANCE: (CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $10.70 - $11.20, vs. FactSet Est of $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2612484704","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612484704?lang=en_us&edition=fundamental","pubTime":"2026-02-18 20:09","pubTimestamp":1771416599,"startTime":"0","endTime":"0","summary":"GUIDANCE: (CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $10.70 - $11.20, vs. FactSet Est of $11","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRL","CRL.AU"],"gpt_icon":0},{"id":"2605476802","title":"A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2605476802","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605476802?lang=en_us&edition=fundamental","pubTime":"2026-01-23 14:52","pubTimestamp":1769151141,"startTime":"0","endTime":"0","summary":"Recent performance snapshot and what it might mean for investors\nCharles River Laboratories International (CRL) has drawn investor attention after recent trading, with the stock closing at $224.03 and showing mixed short term moves alongside stronger returns over the past year.\nOver the past month, the stock return is 10.43%. The past 3 months show a 13.70% gain, and the 1 year total return stands at 34.26%. Short term performance is more muted, with a 0.25% move over the past week and a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-look-at-charles-river-laboratories-crl-valuation-after-rec","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-look-at-charles-river-laboratories-crl-valuation-after-rec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4121","LU0390134368.USD","LU0029874061.USD","BK7095","LU1815336091.USD","LU0128526141.USD","BK4588","BK4530","BK4585","CRL","IE00BFMHRM44.USD","LU0757428866.USD","CRL.AU"],"gpt_icon":0},{"id":"2602351552","title":"Why Charles River (CRL) Is Up 9.1% After Naming Long‑Time Insider Birgit Girshick CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2602351552","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602351552?lang=en_us&edition=fundamental","pubTime":"2026-01-11 22:14","pubTimestamp":1768140871,"startTime":"0","endTime":"0","summary":"Charles River Laboratories International announced that long‑time Chair, President and CEO James C. Foster will retire in May 2026, with current Chief Operating Officer Birgit Girshick appointed as his successor and nominated to join the Board, while Foster remains as a non‑executive Director and the Chair and CEO roles are separated.\nThis transition caps Foster’s 50‑year tenure in which Charles River evolved from a niche research models business into a global preclinical contract research...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/why-charles-river-crl-is-up-91-after-naming-longtime-insider","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/why-charles-river-crl-is-up-91-after-naming-longtime-insider","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0128526141.USD","CRL","LU0029874061.USD","LU1815336091.USD","BK4585","BK4530","BK4588","LU0390134368.USD","BK4121","CRL.AU","BK7095","LU0757428866.USD","IE00BFMHRM44.USD"],"gpt_icon":0},{"id":"2583310595","title":"Did Lower Guidance and Weak Earnings Just Shift Charles River Laboratories' (CRL) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583310595","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583310595?lang=en_us&edition=fundamental","pubTime":"2025-11-13 10:17","pubTimestamp":1763000224,"startTime":"0","endTime":"0","summary":"On November 5, 2025, Charles River Laboratories International reported a year-over-year decrease in revenue and net income for the third quarter, alongside lowering its full-year outlook for revenue growth and earnings per share.\nDespite announcing a new US$1.0 billion share repurchase program, the company reported no new share buybacks in the most recent quarter as operational performance softened.\nWe will explore how the reduced full-year guidance and weaker quarterly earnings reshape...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/did-lower-guidance-and-weak-earnings-just-shift-charles-rive","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/did-lower-guidance-and-weak-earnings-just-shift-charles-rive","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRL.AU","CRL"],"gpt_icon":0},{"id":"2577680363","title":"A Fresh Look at Charles River Laboratories (CRL) Valuation Following Recent Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2577680363","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577680363?lang=en_us&edition=fundamental","pubTime":"2025-10-22 17:29","pubTimestamp":1761125345,"startTime":"0","endTime":"0","summary":"Charles River Laboratories International (CRL) stock has shown steady gains over the past month, returning 21%. Investors are watching recent momentum as the company posts annual revenue and net income growth in its latest financial update.\nSee our latest analysis for Charles River Laboratories International.\nThe recent momentum in Charles River Laboratories International’s shares has grabbed attention, with a 1-month share price return of 21.2% and a solid 7-day gain that signals renewed...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-fresh-look-at-charles-river-laboratories-crl-valuation-fol","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-fresh-look-at-charles-river-laboratories-crl-valuation-fol","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRL","CRL.AU","BK4530","LU0757428866.USD","IE00BFMHRM44.USD","BK4585","LU0390134368.USD","LU1815336091.USD","BK4121","BK7095","BK4588"],"gpt_icon":0},{"id":"2576417866","title":"Charles River Laboratories Collaborates With X-Chem to Boost Hit Identification Capabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2576417866","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576417866?lang=en_us&edition=fundamental","pubTime":"2025-10-20 23:53","pubTimestamp":1760975625,"startTime":"0","endTime":"0","summary":"Charles River Laboratories International  said Monday it has entered into a strategic collaboration with drug discovery firm X-Chem to boost its hit identification capabilities.The partnership gives Charles River clients access to X-Chem's DNA-encoded library with more than 15 billion compounds, according to a statement.Shares of Charles River were up more than 2% in recent trading Monday.Price: 183.20, Change: +4.68, Percent Change: +2.62","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4121","BK4585","LU1815336091.USD","BK4530","LU0390134368.USD","LU0757428866.USD","BK4588","CRL.AU","BK7095","CRL"],"gpt_icon":0},{"id":"2572505635","title":"S&P 500 Posts Weekly Gain to Record Close, Led by Health Care Amid Pfizer Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2572505635","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572505635?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:44","pubTimestamp":1759524242,"startTime":"0","endTime":"0","summary":"The Standard & Poor's 500 index rose 1.1% this week to its highest close ever, boosted by strong gains in the health care sector amid an agreement between Pfizer (PFE) and the Trump administration.The","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UDOW","VOO","MYMmain","UPRO","VLO","NQmain","DAL","CRL","PFE","QID",".IXIC","USAW.SI","CEG","TECH","PSQ","TQQQ","DDM","SSO","OEX","SDS","SPY","PFE.AU",".SPX","QLD","SH","DXD","SDOW","NVIW.SI","ESmain","OEF","PEP","IE00B19Z8W00.USD","STZ","USJW.SI","MESmain","BK4504","DAL.AU","DOG","TECH.AU","MKC","SQQQ","DJX","TMO","MNQmain","SPXU","CRL.AU",".DJI","TSYW.SI","IVV"],"gpt_icon":1},{"id":"2572596547","title":"Charles River Labs Shares Rise After Barclays Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2572596547","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572596547?lang=en_us&edition=fundamental","pubTime":"2025-10-03 02:58","pubTimestamp":1759431497,"startTime":"0","endTime":"0","summary":"Charles River Laboratories (CRL) stock rose 3.6% in recent trading on Thursday after Barclays upgraded the stock to overweight from equal weight.Intraday trading volume stood at over 987,000 shares compared with a daily average of roughly 891,000.Price: 176.69, Change: +6.21, Percent Change: +3.64","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4121","LU0390134368.USD","LU0757428866.USD","BK4530","CRL","LU1815336091.USD","BK7095","CRL.AU","BK4588","BK4585"],"gpt_icon":0},{"id":"2569747879","title":"Charles River Laboratories (CRL): Valuation Perspectives After CFO Transition, Guidance Reaffirmation, and New Oncology Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2569747879","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569747879?lang=en_us&edition=fundamental","pubTime":"2025-09-24 03:42","pubTimestamp":1758656531,"startTime":"0","endTime":"0","summary":"If you are eyeing Charles River Laboratories International (NYSE:CRL) right now, you are not alone. The surprise resignation of CFO Flavia H. Pease has put a major spotlight on the company’s leadership, prompting plenty of armchair questions about what this means for the stock. Instead of letting uncertainty linger, Charles River quickly named an interim CFO and began a search for a permanent replacement. The company also took the opportunity to reaffirm its earnings guidance for the year...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-crl-valuation-perspectives-after","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-crl-valuation-perspectives-after","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRL","BK4121","LU0390134368.USD","BK4530","BK7095","LU0757428866.USD","CRL.AU","BK4585","DCF","BK4588","LU1815336091.USD"],"gpt_icon":0},{"id":"2567104997","title":"Charles River Laboratories Says CFO to Step Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2567104997","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567104997?lang=en_us&edition=fundamental","pubTime":"2025-09-16 19:32","pubTimestamp":1758022344,"startTime":"0","endTime":"0","summary":"Charles River Laboratories International  said Tuesday that Flavia Pease is stepping down as chief financial officer to pursue another opportunity, effective Sept. 29.The company named Chief Accounting Officer Michael Knell as interim CFO and said it has launched an executive search for Pease's successor.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0390134368.USD","BK4530","BK7095","LU0757428866.USD","BK4588","CRL","BK4585","BK4121","CRL.AU","LU1815336091.USD"],"gpt_icon":0},{"id":"2567049921","title":"Insulet Appoints Flavia Pease Finance Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2567049921","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567049921?lang=en_us&edition=fundamental","pubTime":"2025-09-16 19:30","pubTimestamp":1758022257,"startTime":"0","endTime":"0","summary":"Insulet  said Tuesday it has appointed Flavia Pease as chief financial officer, effective Sept. 30.Pease will join the company from Charles River Laboratories , where she most recently served as the CFO. She will succeed Ana Maria Chadwick, who will become a senior adviser to Insulet for a smooth transition, according to the company.Insulet also said it anticipates exceeding its previously issued Q3 total revenue growth outlook due to \"strong\" new customer starts in both the US and global markets.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0728928796.USD","LU2324357040.USD","LU0757428866.USD","LU2065169927.USD","CRL.AU","BK4530","LU1119994496.HKD","LU1815336091.USD","LU0390134368.USD","LU2065171311.SGD","CRL","LU1261432733.SGD","BK4585","BK4082","LU2065171402.SGD","PODD","BK7095","BK4551","LU2065170008.USD","BK4121","LU1084165304.USD","BK4588","BK4566"],"gpt_icon":0},{"id":"2566915913","title":"Charles River Laboratories International (CRL) Expands Oncology Partnerships With PICI and CHLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2566915913","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566915913?lang=en_us&edition=fundamental","pubTime":"2025-09-12 01:29","pubTimestamp":1757611780,"startTime":"0","endTime":"0","summary":"Charles River Laboratories International (CRL) recently announced strategic collaborations to advance oncology research. This news comes amid a 2.91% price increase over the past month. During this period, the broader market, including major indexes like the S&P 500, rose to record highs, bolstered by inflation data indicating potential interest rate cuts by the Federal Reserve. While these macroeconomic factors likely influenced CRL's share price positively, the company's efforts in oncology...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-international-crl-expands-oncolog","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-international-crl-expands-oncolog","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4530","LU1815336091.USD","CRL","BK7095","BK4585","CRL.AU","LU0390134368.USD","LU0757428866.USD","BK4121","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}]}}